The medical care of people with psychosis

Medical Journal of Australia

Volumn 190, Issue 4, 2009, Pages 171-172

  Lambert, Timothy J R ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE;

BIPOLAR DISORDER; COMORBIDITY; DIABETES MELLITUS; DRUG SAFETY; EARLY DIAGNOSIS; EDITORIAL; HUMAN; HYPERLIPIDEMIA; MEDICAL CARE; METABOLIC SYNDROME X; OBESITY; PATIENT ATTITUDE; PATIENT CARE; PROPHYLAXIS; PSYCHOSIS; RISK FACTOR; SCHIZOPHRENIA;

EID: 61849137133     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2009.tb02339.x     Document Type: Editorial

References (17)

1. Lawrence D, Holman C, Jablensky A. Duty to care: preventable physical illness in people with mental illness. Perth: University of Western Australia, 2001. http://www.sph.uwa.edu.au/go/research-programs/ centre-for-health-services-research/consumer-information/ schools-and-centres/schools/school-of-population-health/ duty-to-care-report (accessed Jan 2009).
2. Lambert TJR, Velakoulis D, Pantelis C. Medical comorbidity in schizophrenia. Med J Aust 2003; 178 (9 Suppl): S67-S70.
3. Lambert TJR, Newcomer JW. Are the cardiometabolic complications of schizophrenia still neglected? Barriers to care. Med J Aust 2009; 190 (4 Suppl): S39-S42.
4. Carr VJ, Lewin TJ, Barnard RE, et al. Attitudes and roles of general practitioners in the treatment of schizophrenia compared with community mental health staff and patients. Soc Psychiatry Psychiatr Epidemiol 2004; 39: 78-84.
5. Lacro JF, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002; 63: 892-909.
6. Fitzsimons J, Berk M, Lambert T, et al. A review of clozapine safety. Expert Opin Drug Saf 2005; 4: 731-744.
7. Layland JJ, Liew D, Prior DL. Clozapine-induced cardiotoxicity: a clinical update. Med J Aust 2009; 190: 190-192.
8. Borovik AM, Bosch MM, Watson SL. Ocular pigmentation associated with clozapine. Med J Aust 2009; 190: 210-211.
9. John AP, Koloth R, Dragovic M, Lim SCB. Prevalence of metabolic syndrome among Australians with severe mental illness. Med J Aust 2009; 190: 176-179.
10. Waterreus AJ, Laugharne JDE. Screening for the metabolic syndrome in patients receiving antipsychotic treatment: a proposed algorithm. Med J Aust 2009; 190: 185-189.
11. Lambert TJR, Chapman LH; Consensus Working Group. Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement. Med J Aust 2004; 181: 544-548.
12. Castle D, Lambert T, Melbourne S, et al. A clinical monitoring system for clozapine. Australas Psychiatry 2006; 14: 156-168.
13. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 2008; 31: 811-822.
14. Lambert T, Chen R, Snars J. The ccCHIP metabolic database. http://www.addat.com/page9/page9.html (accessed Jan 2009).
15. Bellivier F. Schizophrenia, antipsychotics and diabetes: genetic aspects. Eur Psychiatry 2005; 20 Suppl 4: S335-S339.
16. Holt RI, Peveler RC. Association between antipsychotic drugs and diabetes. Diabetes Obes Metab 2006; 8: 125-135.
17. Maudsley H. The pathology of mind: a study of its distempers, deformities and disorders. London: Macmillan and Co, 1895.